Orange Book Listing

What It Means

The Orange Book — formally titled "Approved Drug Products with Therapeutic Equivalence Evaluations" — is the FDA's official catalog of all approved prescription and over-the-counter drug products in the United States, along with the patents and exclusivity periods associated with each. It is the authoritative reference that generic drug manufacturers must consult when preparing Abbreviated New Drug Applications (ANDAs), and it plays a central role in pharmaceutical patent strategy. Drug manufacturers submit patent information to the FDA for listing in the Orange Book when their New Drug Applications (NDAs) are approved. The listed patents typically cover the active ingredient, drug formulation, methods of use, or other aspects of the approved product. When a generic manufacturer files an ANDA, it must address each patent listed in the Orange Book for the reference drug through one of four certifications: Paragraph I (no patent listed), Paragraph II (patent has expired), Paragraph III (promise not to market until patent expires), or Paragraph IV (asserting the patent is invalid or not infringed). The Orange Book listing strategy is critical for brand-name companies because the patents listed serve as gatekeepers against generic entry. Companies strategically list patents that provide maximum defensive value, and they continue to add new patents as they are granted — a practice sometimes criticized as "patent thicketing." The Orange Book is publicly available and updated monthly, making it an essential resource for tracking pharmaceutical patent landscapes. Generic companies, investors, and patent analysts all monitor Orange Book changes to anticipate when generic competition may emerge for specific drugs.

Frequently Asked Questions